Novo Nordisk (NYSE: NVO) details progress on DKK 15B share repurchase

Rhea-AI Filing Summary

Novo Nordisk A/S reports progress on its ongoing share repurchase programme. The company plans to buy back up to DKK 15 billion of B shares over a 12‑month period beginning 4 February 2026, as part of a capital return strategy under EU Safe Harbour rules.

Within a sub-programme of up to DKK 3.8 billion running from 4 February to 4 May 2026, Novo Nordisk has repurchased 11,007,992 B shares at an average price of DKK 257.56, for a total of DKK 2,835,176,799 as of 10 April 2026. The company now holds 28,397,791 B shares in treasury, equal to 0.6% of its total share capital of 4,465,000,000 A and B shares.

Key Figures

Total buyback programme size: DKK 15 billion Current sub-programme size: DKK 3.8 billion Shares repurchased to date: 11,007,992 B shares +4 more

7 metrics

Total buyback programme size DKK 15 billion Planned B share repurchases over 12 months from 4 February 2026

Current sub-programme size DKK 3.8 billion B share repurchases from 4 February 2026 to 4 May 2026

Shares repurchased to date 11,007,992 B shares Total repurchased from 4 February 2026 to 10 April 2026

Average repurchase price DKK 257.56 per B share Average price for 11,007,992 B shares since 4 February 2026

Total repurchase value DKK 2,835,176,799 Value of 11,007,992 B shares repurchased as of 10 April 2026

Treasury shares held 28,397,791 B shares B treasury shares corresponding to 0.6% of share capital

Total share capital 4,465,000,000 shares Total A and B shares outstanding including treasury shares

Key Terms

share repurchase programme, treasury shares, Safe Harbour Rules, Regulation No 596/2014, +1 more

5 terms

share repurchase programme financial

"Novo Nordisk initiated a share repurchase programme in accordance with Article 5"

A share repurchase programme is a company's plan to buy back its own shares from the market. This reduces the total number of shares available, which can increase the value of remaining shares and signal confidence in the company's health. For investors, it can indicate that the company believes its stock is undervalued and may lead to higher share prices.

treasury shares financial

"Novo Nordisk owns a total of 28,397,791 B shares of DKK 0.10 as treasury shares"

Treasury shares are a company’s own stock that it has repurchased and keeps on its books instead of canceling or leaving in the hands of outside investors. Think of them like coupons a business puts back in a drawer: they don’t vote or receive dividends while held, but they can be reissued later for employee pay or fundraising. For investors this matters because buybacks change the number of shares that count toward earnings and ownership, can boost per‑share metrics, and use corporate cash that might otherwise go to growth or dividends.

Safe Harbour Rules regulatory

"in accordance with ... the Commission Delegated Regulation (EU) 2016/1052 ... (the "Safe Harbour Rules")"

Regulation No 596/2014 regulatory

"in accordance with Article 5 of Regulation No 596/2014 of the European Parliament"

Commission Delegated Regulation (EU) 2016/1052 regulatory

"and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________

FORM 6-K

________________

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

April 13, 2026

________________

NOVO NORDISK A/S

 (Exact name of Registrant as specified in its charter)

Novo Allé 1

DK- 2880, Bagsvaerd

Denmark

(Address of principal executive offices)

________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒           Form 40-F ☐

 

 

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 13 April 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.

Under the programme initiated 4 February 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 3.8 billion in the period from 4 February 2026 to 4 May 2026.

Since the announcement 7 April 2026, the following transactions have been made:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	9,967,992		2,586,404,548
7 April 2026	260,000	235.50	61,229,022
8 April 2026	260,000	242.28	62,993,029
9 April 2026	260,000	236.25	61,424,153
10 April 2026	260,000	242.79	63,126,047
Accumulated under the programme	11,007,992		2,835,176,799

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 28,397,791 B shares of DKK 0.10 as treasury shares, corresponding to 0.6% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.

Page 2 of 2

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 10 April 2026, Novo Nordisk has since 4 February 2026 repurchased a total 11,007,992 B shares at an average share price of DKK 257.56 per B share equal to a transaction value of DKK 2,835,176,799.

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Media:
Ambre James-Brown +45 3079 9289 globalmedia@novonordisk.com	Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com
Investors:
Michael Novod +45 3075 6050 nvno@novonordisk.com	Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com
Max Ung +45 3077 6414 mxun@novonordisk.com	Sina Meyer +45 3079 6656 azey@novonordisk.com
Alex Bruce +45 34 44 26 13 axeu@novonordisk.com	Christoffer Sho Togo Tullin +45 3079 1471 cftu@novonordisk.com
Frederik Taylor Pitter +1 609 613 0568 fptr@novonordisk.com	Mads Berner Bruun +45 3075 2936 mbbz@novonordisk.com

Novo Nordisk A/S Investor Relations	Novo Allé 1 2880 Bagsværd Denmark	Telephone: +45 4444 8888	www.novonordisk.com CVR no: 24 25 67 90
			Company announcement No 25 / 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: April 13, 2026   NOVO NORDISK A/S   Maziar Mike Doustdar Chief Executive Officer

FAQ

What share buyback programme did Novo Nordisk (NVO) confirm in this 6-K?

Novo Nordisk confirmed a share repurchase programme of up to DKK 15 billion in B shares over a 12-month period starting 4 February 2026, conducted under EU Safe Harbour rules. This is part of its broader capital return approach to shareholders.

How many Novo Nordisk B shares have been repurchased so far in 2026?

As of 10 April 2026, Novo Nordisk has repurchased 11,007,992 B shares since 4 February 2026. These shares were bought at an average price of DKK 257.56, corresponding to a total transaction value of DKK 2,835,176,799 under the current programme.

What portion of Novo Nordisk’s share capital is held as treasury shares?

Novo Nordisk now holds 28,397,791 B shares of DKK 0.10 as treasury shares, representing 0.6% of its total share capital. The combined number of A and B shares, including treasury shares, is 4,465,000,000 according to the filing.

What is the size and timing of Novo Nordisk’s current sub-programme?

Under the current sub-programme, Novo Nordisk plans to repurchase B shares for up to DKK 3.8 billion from 4 February 2026 to 4 May 2026. This sub-programme forms part of the larger DKK 15 billion buyback framework disclosed by the company.

Where can investors find detailed daily transactions for Novo Nordisk’s buyback?

The company states that details for each transaction under the share repurchase programme are published on novonordisk.com. Investors can review daily numbers of B shares repurchased, average purchase prices, and transaction values directly through Novo Nordisk’s investor information channels.

On which exchanges are Novo Nordisk securities listed?

Novo Nordisk’s B shares are listed on Nasdaq Copenhagen under the symbol Novo-B. Its American Depositary Receipts (ADRs) are listed on the New York Stock Exchange under the ticker NVO, giving investors access in both European and U.S. markets.